Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 121

Showing 26-50 of 121 citing articles:

From Emergence to Endemicity: A Comprehensive Review of COVID-19
Roopa Naik, Sreekant Avula, Sujith K Palleti, et al.
Cureus (2023)
Open Access | Times Cited: 11
Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials
Massimo Franchini, Mario Cruciani, Arturo Casadevall, et al.
Transfusion (2023) Vol. 64, Iss. 2, pp. 388-399
Closed Access | Times Cited: 11
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study
Sammy Huygens, Tim Preijers, Francis Swaneveld, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 4, pp. 497-509
Open Access | Times Cited: 3
Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report
Bénédicte Billi, Paul Cholley, Vincent Grobost, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients
Yan Leyfman, Nancy Emmanuel, Gayathri P. Menon, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 9
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
Alina Seidel, Simone Hoffmann, Bernd Jahrsdörfer, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 17
WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
Massimo Franchini, Arturo Casadevall, Michael J. Joyner, et al.
Life (2023) Vol. 13, Iss. 1, pp. 134-134
Open Access | Times Cited: 8
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 2
Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID‐19
Tsofia Inbar, Eldad J. Dann, Omer Kerner, et al.
Transfusion (2024) Vol. 64, Iss. 3, pp. 443-448
Closed Access | Times Cited: 2
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 2
“A Most Equitable Drug”: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development
Quinn Grundy, Chantal Campbell, Ridwaanah Ali, et al.
The Journal of Law Medicine & Ethics (2024) Vol. 52, Iss. 1, pp. 80-97
Open Access | Times Cited: 2
Convalescent Plasma and the US Expanded Access Program: A Personal Narrative
Michael J. Joyner
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 2
Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship
Arturo Casadevall, Daniele Focosi, Liise-anne Pirofski, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 6, pp. 1404-1407
Closed Access | Times Cited: 2
Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease
Hyunah Yoon, Liise‐anne Pirofski
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 2
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19
Shunyao Chen, Cong Zhang, Deng Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Coagulopathy and thromboembolic events a pathogenic mechanism of COVID‐19 associated with mortality: An updated review
Parastoo Yousefi, Saber Soltani, Goli Siri, et al.
Journal of Clinical Laboratory Analysis (2023) Vol. 37, Iss. 11-12
Open Access | Times Cited: 7
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Moisés A. Huamán, Jay S. Raval, James H. Paxton, et al.
Transfusion (2023) Vol. 63, Iss. 9, pp. 1639-1648
Open Access | Times Cited: 7
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants
Hannes Lindahl, Puran Chen, Mikael Åberg, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1075-1082
Open Access | Times Cited: 6
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients
Sabina Herrera, José María Aguado, Francisco Javier Candel, et al.
Transplantation Reviews (2023) Vol. 37, Iss. 4, pp. 100788-100788
Closed Access | Times Cited: 6
Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients
Massimo Franchini, Arturo Casadevall, Jonathon W. Senefeld, et al.
Seminars in Thrombosis and Hemostasis (2023) Vol. 50, Iss. 04, pp. 648-653
Closed Access | Times Cited: 6
Survey of treatment practices for immunocompromised patients with COVID‐19 in Australasia
Michael A. Moso, Joe Sasadeusz, C. Orla Morrissey, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 4, pp. 619-624
Open Access | Times Cited: 5
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Cameron Y. S. Lee, Jon B. Suzuki
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2055-2055
Open Access | Times Cited: 5

Scroll to top